Aquestive Therapeutics (AQUA)
AQUA
CNS
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- CNSsrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Alopecia Areata: Current and Emerging Therapies. — Drugs 2026 Aug 19 PMID 42616344
- The pro-doc-tivity pause: Health economic benefits of collegial connection. — Ann Allergy Asthma Immunol 2026 Jul PMID 41999987
- 'What' and 'How' to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes. — Clin Exp Allergy 2026 May PMID 41974646
- The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy. — CNS Drugs 2026 Jul PMID 41951906
- Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. — J Allergy Clin Immunol 2026 May PMID 41794053
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Aquestive Therapeutics.
Full AQUA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.